Efficacy Study of CPC634 (CriPec® Docetaxel) in Platinum Resistant Ovarian Cancer

NCT03742713 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Ovarian Cancer

Interventions

DRUG: CPC634 (CriPec® docetaxel)

Sponsor

Cristal Therapeutics